AC Immune (NASDAQ:ACIU – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday.
A number of other brokerages have also weighed in on ACIU. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of AC Immune in a research note on Wednesday, September 18th. BTIG Research started coverage on AC Immune in a research note on Friday, May 31st. They set a “buy” rating and a $8.00 price target on the stock.
Read Our Latest Report on ACIU
AC Immune Stock Performance
AC Immune (NASDAQ:ACIU – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $91.60 million. On average, sell-side analysts predict that AC Immune will post -0.89 earnings per share for the current year.
Institutional Trading of AC Immune
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC acquired a new stake in AC Immune in the 2nd quarter valued at $40,000. Lazard Asset Management LLC acquired a new stake in AC Immune in the 1st quarter valued at $30,000. BNP Paribas Financial Markets increased its holdings in AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after purchasing an additional 8,423 shares in the last quarter. Vanguard Capital Wealth Advisors acquired a new stake in AC Immune in the 2nd quarter valued at $56,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in AC Immune by 96.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock valued at $56,000 after purchasing an additional 9,334 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors and hedge funds.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Stories
- Five stocks we like better than AC Immune
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- The Average 401k Balance by Age Explained
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.